Homer Pearce
Director/Board Member bei BioNumerik Pharmaceuticals, Inc.
Profil
Homer L.
Pearce is currently a Director at BioNumerik Pharmaceuticals, Inc., a Director at Apexian Pharmaceuticals, Inc., a Member of the American Chemical Society, a Member of the American Association for Cancer Research, and an Advisory Board member at Accelerator Services Corp.
Previously, he was an Independent Director at Sunesis Pharmaceuticals, Inc. from 2006 to 2021, a Director & Scientific Advisor at Kylin Therapeutics, Inc. from 2009 to 2013, a Director at BlinkBio, Inc., a Director at Catena Pharmaceuticals, Inc., and the VP-Cancer Research & Clinical Investigation at Eli Lilly & Co. from 1994 to 2006.
He was also a Member of the American Association for the Advancement of Science.
Pearce received his doctorate from Harvard University in 1979 and his undergraduate degree from Texas A&M University in 1974.
Aktive Positionen von Homer Pearce
Unternehmen | Position | Beginn |
---|---|---|
American Association for Cancer Research
American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA. | Corporate Officer/Principal | - |
American Chemical Society
American Chemical Society Miscellaneous Commercial ServicesCommercial Services American Chemical Society engages as a scientific society which supports scientific inquiry in the field of chemistry. The company was founded in 1876 and is headquartered in Washington, DC. | Corporate Officer/Principal | - |
BioNumerik Pharmaceuticals, Inc.
BioNumerik Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology BioNumerik Pharmaceuticals, Inc. discovers and develops new medicines for cancer treatment. The firm's products include Tavocept which has the potential to substantially increase patient survival in the most common type of lung cancer and possibly many other forms of cancer, and Karenitecin which is an investigational new anti-tumor drug in the camptothecin class of chemotherapy drugs. The company was founded by Frederick H. Hausheer on December 15, 1992 and is headquartered in San Antonio, TX. | Director/Board Member | - |
Apexian Pharmaceuticals, Inc.
Apexian Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Apexian Pharmaceuticals, Inc. discovers, develops and commercializes novel pharmaceuticals products. It offers pharmaceutical products for the treatment of pancreatic cancer, blood cancer, brain tumors, ovarian cancer, age-related macular degeneration, and diabetic retinopathy. The company was founded by Mark R. Kelley in 2005 and is headquartered in Indianapolis, IN. | Director/Board Member | - |
Accelerator Services Corp
Accelerator Services Corp Investment ManagersFinance Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington. | Consultant / Advisor | - |
Ehemalige bekannte Positionen von Homer Pearce
Unternehmen | Position | Ende |
---|---|---|
VIRACTA THERAPEUTICS, INC. | Director/Board Member | 24.02.2021 |
Catena Pharmaceuticals, Inc.
Catena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Catena Pharmaceuticals, Inc. is focused on the development and commercialization of novel GPCR antagonists, particularly in the areas of cancer and fibrotic disease. Catena's proprietary chemistry is uniquely capable of affecting a specific class of GPCRs known to be relevant in a variety of disease states. Catena focuses its research and product development efforts around manipulation of the biology of the blood-borne signaling molecule lysophosphatidic acid (LPA). Its products will either block the signaling of LPA, or reduce production of LPA, or mimic LPA. The company was founded by Kevin Lynch and Tim MacDonald in the year 2008 and is headquartered in Durham, NC. | Director/Board Member | 09.07.2013 |
Kylin Therapeutics, Inc.
Kylin Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Kylin Therapeutics, Inc., a cutting-edge biotechnology company, employs a revolutionary RNA nanoparticle technology platform called 'pRNA' to exploit the enormous potential of RNA interference (RNAi) for treatment of many common diseases. This visionary platform has enormous potential to meet the huge market opportunity for treating cancer and other diseases with RNA-based therapeutics. The unique capabilities of the platform have enabled Kylin to overcome the most significant challenges in the development of RNA-based therapies. The formation of Kylin Therapeutics Inc., is a result of a joint partnership between IN-vivo Ventures, LLC, and Golden Pine Ventures, LLC. Together, these two companies can leverage their alliance partners and strong Board of Directors to ensure Kylin's success. A lean, cross-functional management team is set to effect early stage success. This team provides the essential ingredients to develop and promote Kylin to the next level. It is the goal of this team to provide early stage validation and market traction to attract world-class operational management with relevant credentials, track records, and operational experience. | Director/Board Member | 01.07.2013 |
ELI LILLY AND COMPANY | Chief Tech/Sci/R&D Officer | 01.03.2002 |
░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Ausbildung von Homer Pearce
Harvard University | Doctorate Degree |
Texas A&M University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ELI LILLY AND COMPANY | Health Technology |
Private Unternehmen | 10 |
---|---|
BioNumerik Pharmaceuticals, Inc.
BioNumerik Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology BioNumerik Pharmaceuticals, Inc. discovers and develops new medicines for cancer treatment. The firm's products include Tavocept which has the potential to substantially increase patient survival in the most common type of lung cancer and possibly many other forms of cancer, and Karenitecin which is an investigational new anti-tumor drug in the camptothecin class of chemotherapy drugs. The company was founded by Frederick H. Hausheer on December 15, 1992 and is headquartered in San Antonio, TX. | Health Technology |
Sunesis Pharmaceuticals, Inc.
Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Kylin Therapeutics, Inc.
Kylin Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Kylin Therapeutics, Inc., a cutting-edge biotechnology company, employs a revolutionary RNA nanoparticle technology platform called 'pRNA' to exploit the enormous potential of RNA interference (RNAi) for treatment of many common diseases. This visionary platform has enormous potential to meet the huge market opportunity for treating cancer and other diseases with RNA-based therapeutics. The unique capabilities of the platform have enabled Kylin to overcome the most significant challenges in the development of RNA-based therapies. The formation of Kylin Therapeutics Inc., is a result of a joint partnership between IN-vivo Ventures, LLC, and Golden Pine Ventures, LLC. Together, these two companies can leverage their alliance partners and strong Board of Directors to ensure Kylin's success. A lean, cross-functional management team is set to effect early stage success. This team provides the essential ingredients to develop and promote Kylin to the next level. It is the goal of this team to provide early stage validation and market traction to attract world-class operational management with relevant credentials, track records, and operational experience. | Commercial Services |
BlinkBio, Inc.
BlinkBio, Inc. Pharmaceuticals: MajorHealth Technology BlinkBio, Inc. operates as a biotechnology company. It develops medicines for the treatment of cancer and other diseases. The company was founded by Maneesh Pingle, Francis Barany, Don Bergstrom and Michael Gargano in 2009 and is headquartered in Juno Beach, FL. | Health Technology |
American Chemical Society
American Chemical Society Miscellaneous Commercial ServicesCommercial Services American Chemical Society engages as a scientific society which supports scientific inquiry in the field of chemistry. The company was founded in 1876 and is headquartered in Washington, DC. | Commercial Services |
American Association for the Advancement of Science
American Association for the Advancement of Science Miscellaneous Commercial ServicesCommercial Services The American Association for the Advancement of Science provides science related journal, program, and education services. The firm also promotes the responsible use of science in public policy. The company was founded in 1848 and is headquartered in Washington, DC. | Commercial Services |
American Association for Cancer Research
American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA. | Commercial Services |
Accelerator Services Corp
Accelerator Services Corp Investment ManagersFinance Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington. | Finance |
Catena Pharmaceuticals, Inc.
Catena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Catena Pharmaceuticals, Inc. is focused on the development and commercialization of novel GPCR antagonists, particularly in the areas of cancer and fibrotic disease. Catena's proprietary chemistry is uniquely capable of affecting a specific class of GPCRs known to be relevant in a variety of disease states. Catena focuses its research and product development efforts around manipulation of the biology of the blood-borne signaling molecule lysophosphatidic acid (LPA). Its products will either block the signaling of LPA, or reduce production of LPA, or mimic LPA. The company was founded by Kevin Lynch and Tim MacDonald in the year 2008 and is headquartered in Durham, NC. | Health Technology |
Apexian Pharmaceuticals, Inc.
Apexian Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Apexian Pharmaceuticals, Inc. discovers, develops and commercializes novel pharmaceuticals products. It offers pharmaceutical products for the treatment of pancreatic cancer, blood cancer, brain tumors, ovarian cancer, age-related macular degeneration, and diabetic retinopathy. The company was founded by Mark R. Kelley in 2005 and is headquartered in Indianapolis, IN. | Health Technology |